We are thrilled to share the exciting news that Ms. Jennifer Che, our President and Managing Director, has been once again recognized on the IAM Strategy 300: The World's Leading IP Strategists of the year for 2025.


The IAM Strategy 300 is a guide to the pioneers in the industry. It recognizes individuals who are “leading the way in developing and implementing strategies that maximize the value of IP portfolios.” Individuals are nominated by the community, and only those identified by market sources for their “exceptional skill sets and profound insights into patent matters” are featured in the IAM Strategy 300. Jennifer's inclusion on this list underscores her outstanding credentials and unique strengths.


With a robust 20-year career as a scientist, patent attorney, and executive, Jennifer has helped numerous companies, institutions, inventors, and start-ups devise effective global intellectual property (IP) strategies. She excels at crafting integrated IP solutions that involve technical, regulatory, and long-range business needs. Jennifer's extensive experience in the U.S. and Greater China gives her a distinctive strategic eye for navigating complex cross-border IP challenges.


Jennifer is a highly regarded speaker and regularly gives talks in Hong Kong, Mainland China, the US, and around the world. She is also the founder and a frequent author of the blog chinapatentstrategy.com.
Please join us in congratulating Jennifer on this well-deserved recognition. Her expertise and dedication to her work make her an invaluable asset to our team and our clients.

Our Past Events

Recommended Insights

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

27 June 2024
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]

China Finally Clamps Down on Facial Recognition Technology

24 August 2021
Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Around the end of July 2021, the Supreme People’s Court issued a new Provision concerning the application of law about a super-hot technology, facial recognition. This Provision is a legal explanation from the SPC explaining how the law should be applied or interpreted […]

China Releases Draft Implementation Guidelines for the Drug Administration Law

2 June 2022
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]

Thin Disclosure but "Bulletproof" Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data

8 January 2026
In China, innovative drug companies typically rely on their initial composition of matter patents to block out competitors. Other “follow-on” IP, such as those directed towards formulations, polymorphs, and salt forms, are often regarded as less likely to survive invalidation challenges, especially in China where the standard of “person skilled in the art” is so […]
Top crossarrow-right